NO944517L - Kvarternært nitrogenholdige fosfonatforbindelser for behandling av unormal kalsium- og fosfatmetabolisme - Google Patents
Kvarternært nitrogenholdige fosfonatforbindelser for behandling av unormal kalsium- og fosfatmetabolismeInfo
- Publication number
- NO944517L NO944517L NO944517A NO944517A NO944517L NO 944517 L NO944517 L NO 944517L NO 944517 A NO944517 A NO 944517A NO 944517 A NO944517 A NO 944517A NO 944517 L NO944517 L NO 944517L
- Authority
- NO
- Norway
- Prior art keywords
- present
- treatment
- quaternary nitrogen
- phosphate metabolism
- abnormal calcium
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract 2
- 229910019142 PO4 Inorganic materials 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 229910052791 calcium Inorganic materials 0.000 title abstract 2
- 239000011575 calcium Substances 0.000 title abstract 2
- 230000004060 metabolic process Effects 0.000 title abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title abstract 2
- 239000010452 phosphate Substances 0.000 title abstract 2
- -1 nitrogen-containing phosphonate compounds Chemical class 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89148792A | 1992-05-29 | 1992-05-29 | |
| US08/052,694 US5753634A (en) | 1992-05-29 | 1993-04-30 | Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism |
| PCT/US1993/005044 WO1993024499A1 (en) | 1992-05-29 | 1993-05-27 | Quaternary nitrogen-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO944517D0 NO944517D0 (no) | 1994-11-25 |
| NO944517L true NO944517L (no) | 1995-01-30 |
Family
ID=26730951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO944517A NO944517L (no) | 1992-05-29 | 1994-11-25 | Kvarternært nitrogenholdige fosfonatforbindelser for behandling av unormal kalsium- og fosfatmetabolisme |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0643716B1 (fi) |
| JP (1) | JPH07507321A (fi) |
| CN (1) | CN1043424C (fi) |
| AT (1) | ATE187456T1 (fi) |
| AU (1) | AU663394B2 (fi) |
| CA (1) | CA2136821C (fi) |
| CZ (1) | CZ296094A3 (fi) |
| DE (1) | DE69327240T2 (fi) |
| DK (1) | DK0643716T3 (fi) |
| ES (1) | ES2139013T3 (fi) |
| FI (1) | FI945597A (fi) |
| GR (1) | GR3032452T3 (fi) |
| HK (1) | HK1014000A1 (fi) |
| HU (1) | HUT69698A (fi) |
| IL (1) | IL105836A (fi) |
| MX (1) | MX9303248A (fi) |
| NO (1) | NO944517L (fi) |
| NZ (1) | NZ253542A (fi) |
| PT (1) | PT643716E (fi) |
| SK (1) | SK144794A3 (fi) |
| WO (1) | WO1993024499A1 (fi) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763611A (en) * | 1992-05-29 | 1998-06-09 | The Procter & Gamble Company | Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| US5753633A (en) * | 1997-04-11 | 1998-05-19 | Colgate-Palmolive Company | Method of inhibiting bone resorption |
| US8676882B2 (en) | 2007-02-27 | 2014-03-18 | Sony Corporation | System and method for preloading content segments to client devices in an electronic network |
| US7781418B2 (en) * | 2006-12-14 | 2010-08-24 | Isis Innovation Ltd. | Composition for treating bone disorders |
| US8816082B2 (en) | 2010-05-28 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| US9290526B2 (en) | 2010-05-28 | 2016-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687768A (en) * | 1984-12-21 | 1987-08-18 | The Procter & Gamble Company | Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism |
| PH27078A (en) * | 1984-12-21 | 1993-02-01 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonates |
| DE4011777A1 (de) * | 1989-04-14 | 1990-10-18 | Ciba Geigy Ag | N-trisubstituierte aminoalkandiphosphonsaeuren |
-
1993
- 1993-05-27 DK DK93914198T patent/DK0643716T3/da active
- 1993-05-27 DE DE69327240T patent/DE69327240T2/de not_active Expired - Fee Related
- 1993-05-27 SK SK1447-94A patent/SK144794A3/sk unknown
- 1993-05-27 CA CA002136821A patent/CA2136821C/en not_active Expired - Fee Related
- 1993-05-27 JP JP6500768A patent/JPH07507321A/ja active Pending
- 1993-05-27 EP EP93914198A patent/EP0643716B1/en not_active Expired - Lifetime
- 1993-05-27 NZ NZ253542A patent/NZ253542A/en unknown
- 1993-05-27 WO PCT/US1993/005044 patent/WO1993024499A1/en not_active Application Discontinuation
- 1993-05-27 HU HU9403410A patent/HUT69698A/hu unknown
- 1993-05-27 PT PT93914198T patent/PT643716E/pt unknown
- 1993-05-27 AT AT93914198T patent/ATE187456T1/de not_active IP Right Cessation
- 1993-05-27 ES ES93914198T patent/ES2139013T3/es not_active Expired - Lifetime
- 1993-05-27 CZ CZ942960A patent/CZ296094A3/cs unknown
- 1993-05-27 AU AU43946/93A patent/AU663394B2/en not_active Ceased
- 1993-05-28 IL IL10583693A patent/IL105836A/en not_active IP Right Cessation
- 1993-05-29 CN CN93108227A patent/CN1043424C/zh not_active Expired - Fee Related
- 1993-05-31 MX MX9303248A patent/MX9303248A/es not_active IP Right Cessation
-
1994
- 1994-11-25 NO NO944517A patent/NO944517L/no unknown
- 1994-11-28 FI FI945597A patent/FI945597A/fi unknown
-
1998
- 1998-12-21 HK HK98114254A patent/HK1014000A1/xx not_active IP Right Cessation
-
2000
- 2000-01-21 GR GR20000400147T patent/GR3032452T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI945597A (fi) | 1995-01-25 |
| EP0643716B1 (en) | 1999-12-08 |
| SK144794A3 (en) | 1995-08-09 |
| HU9403410D0 (en) | 1995-02-28 |
| ES2139013T3 (es) | 2000-02-01 |
| DE69327240D1 (de) | 2000-01-13 |
| NO944517D0 (no) | 1994-11-25 |
| DK0643716T3 (da) | 2000-03-27 |
| JPH07507321A (ja) | 1995-08-10 |
| EP0643716A1 (en) | 1995-03-22 |
| CA2136821A1 (en) | 1993-12-09 |
| HUT69698A (en) | 1995-09-28 |
| HK1014000A1 (en) | 1999-09-17 |
| AU663394B2 (en) | 1995-10-05 |
| GR3032452T3 (en) | 2000-05-31 |
| CN1043424C (zh) | 1999-05-19 |
| WO1993024499A1 (en) | 1993-12-09 |
| IL105836A0 (en) | 1993-09-22 |
| DE69327240T2 (de) | 2000-07-20 |
| CA2136821C (en) | 1999-06-15 |
| FI945597A0 (fi) | 1994-11-28 |
| AU4394693A (en) | 1993-12-30 |
| IL105836A (en) | 1999-11-30 |
| ATE187456T1 (de) | 1999-12-15 |
| CN1085909A (zh) | 1994-04-27 |
| NZ253542A (en) | 1997-01-29 |
| MX9303248A (es) | 1994-05-31 |
| PT643716E (pt) | 2000-05-31 |
| CZ296094A3 (en) | 1995-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU94046137A (ru) | Фосфонсульфонатные соединения для лечения аномального кальциевого и фосфатного обмена, фармацевтическая композиция | |
| NO944515D0 (no) | Fosfonkarboksylatforbindelser for behandling av abnormal kalsium- og fosfatmetabolisme | |
| RU94046146A (ru) | Тиозамещенные азотсодержащие гетероциклические фосфонатные соединения, фармкомпозиция и способ лечения | |
| CA2136825A1 (en) | Quaternary Nitrogen-Containing Phosphonate Compounds, for Treating Abnormal Calcium and Phosphate Metabolism as Well as Dental Calculus and Plaque | |
| NO944517D0 (no) | Kvarternære nitrogen-inneholdende fosfonatforbindelser for behandling av abnormal kalsium- og fosfatmetabolisme | |
| FI945592A (fi) | Fosfonosulfonaattiyhdisteitä epänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi | |
| RU94046103A (ru) | Содержащие четвертичный азот фосфонатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция, способ лечения | |
| CA2136822A1 (en) | Thio-Substituted Cyclic Phosphonate Compounds for Treating Abnormal Calcium and Phosphate Metabolism | |
| RU94046139A (ru) | Содержащие четвертичный азот фосфанатные соединения для лечения аномального кальциевого и фосфатного метаболизма, фармацевтическая композиция | |
| NO944514L (no) | Kvarternære nitrogen-inneholdende fosfonatforbindelser for behandling av abnormal kalsium- og fosfatmetabolisme |